Patients satisfaction with warfarin and willingness to switch to dabigatran

A patient survey

Hazem F. Elewa, Christina E. DeRemer, Kimble Keller, Jaspal S Gujral, Thomas Vayalinkara Joshua

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Warfarin is an anticoagulant medication that is challenging to manage. Dabigatran has been approved by the FDA for stroke and systemic embolism prevention in non-valvular atrial fibrillation as an alternative to warfarin. Dabigatran does not require routine monitoring, has an established dose, and lacks many of the drug, herbal, and food interactions that afflict warfarin. To evaluate patients' satisfaction with their current warfarin treatment and their opinion on switching to a newly marketed medication (dabigatran) through a brief survey. Two separate surveys were administered to (1) evaluate the patients' opinion of their warfarin therapy and (2) evaluate their thoughts on switching to a newer anticoagulant. Responses were recorded on a rating scale of 1-5; 1 being the least and 5 being the highest. Study was conducted at the Georgia Regents Health System (GRHS) pharmacy-based anticoagulation clinic. Two hundred sixty patients on warfarin treatment were enrolled. Patients expressed high satisfaction with warfarin treatment (4.7 ± 0.78). However, a vast majority of the patients were willing to switch to an agent that: requires less frequent follow-up visits (3.9 ± 1.35); lacks interaction with food and/or beverage (4.1 ± 1.25); is as efficacious as warfarin (3.7 ± 1.38). Patients expressed that out-of-pocket cost would be a major barrier to switch to this new medication (1.3 ± 0.58). Patients are satisfied with their warfarin treatment but willing to consider a new anticoagulant. Cost was highlighted as the most significant barrier. Efficacy, dietary freedom and less frequent visits are the major factors affecting the patients' decision.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Warfarin
Patient Satisfaction
Anticoagulants
Food-Drug Interactions
Therapeutics
Dabigatran
Surveys and Questionnaires
Food and Beverages
Health Expenditures
Embolism
Atrial Fibrillation
Stroke
Costs and Cost Analysis
Health

Keywords

  • Atrial fibrillation
  • Dabigatran
  • New oral anticoagulants
  • Warfarin

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Patients satisfaction with warfarin and willingness to switch to dabigatran : A patient survey. / Elewa, Hazem F.; DeRemer, Christina E.; Keller, Kimble; Gujral, Jaspal S; Joshua, Thomas Vayalinkara.

In: Journal of Thrombosis and Thrombolysis, Vol. 38, No. 1, 01.01.2014, p. 115-120.

Research output: Contribution to journalArticle

@article{a9efb12fe5dd403bbbaa988614a3467f,
title = "Patients satisfaction with warfarin and willingness to switch to dabigatran: A patient survey",
abstract = "Warfarin is an anticoagulant medication that is challenging to manage. Dabigatran has been approved by the FDA for stroke and systemic embolism prevention in non-valvular atrial fibrillation as an alternative to warfarin. Dabigatran does not require routine monitoring, has an established dose, and lacks many of the drug, herbal, and food interactions that afflict warfarin. To evaluate patients' satisfaction with their current warfarin treatment and their opinion on switching to a newly marketed medication (dabigatran) through a brief survey. Two separate surveys were administered to (1) evaluate the patients' opinion of their warfarin therapy and (2) evaluate their thoughts on switching to a newer anticoagulant. Responses were recorded on a rating scale of 1-5; 1 being the least and 5 being the highest. Study was conducted at the Georgia Regents Health System (GRHS) pharmacy-based anticoagulation clinic. Two hundred sixty patients on warfarin treatment were enrolled. Patients expressed high satisfaction with warfarin treatment (4.7 ± 0.78). However, a vast majority of the patients were willing to switch to an agent that: requires less frequent follow-up visits (3.9 ± 1.35); lacks interaction with food and/or beverage (4.1 ± 1.25); is as efficacious as warfarin (3.7 ± 1.38). Patients expressed that out-of-pocket cost would be a major barrier to switch to this new medication (1.3 ± 0.58). Patients are satisfied with their warfarin treatment but willing to consider a new anticoagulant. Cost was highlighted as the most significant barrier. Efficacy, dietary freedom and less frequent visits are the major factors affecting the patients' decision.",
keywords = "Atrial fibrillation, Dabigatran, New oral anticoagulants, Warfarin",
author = "Elewa, {Hazem F.} and DeRemer, {Christina E.} and Kimble Keller and Gujral, {Jaspal S} and Joshua, {Thomas Vayalinkara}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11239-013-0976-y",
language = "English (US)",
volume = "38",
pages = "115--120",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Patients satisfaction with warfarin and willingness to switch to dabigatran

T2 - A patient survey

AU - Elewa, Hazem F.

AU - DeRemer, Christina E.

AU - Keller, Kimble

AU - Gujral, Jaspal S

AU - Joshua, Thomas Vayalinkara

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Warfarin is an anticoagulant medication that is challenging to manage. Dabigatran has been approved by the FDA for stroke and systemic embolism prevention in non-valvular atrial fibrillation as an alternative to warfarin. Dabigatran does not require routine monitoring, has an established dose, and lacks many of the drug, herbal, and food interactions that afflict warfarin. To evaluate patients' satisfaction with their current warfarin treatment and their opinion on switching to a newly marketed medication (dabigatran) through a brief survey. Two separate surveys were administered to (1) evaluate the patients' opinion of their warfarin therapy and (2) evaluate their thoughts on switching to a newer anticoagulant. Responses were recorded on a rating scale of 1-5; 1 being the least and 5 being the highest. Study was conducted at the Georgia Regents Health System (GRHS) pharmacy-based anticoagulation clinic. Two hundred sixty patients on warfarin treatment were enrolled. Patients expressed high satisfaction with warfarin treatment (4.7 ± 0.78). However, a vast majority of the patients were willing to switch to an agent that: requires less frequent follow-up visits (3.9 ± 1.35); lacks interaction with food and/or beverage (4.1 ± 1.25); is as efficacious as warfarin (3.7 ± 1.38). Patients expressed that out-of-pocket cost would be a major barrier to switch to this new medication (1.3 ± 0.58). Patients are satisfied with their warfarin treatment but willing to consider a new anticoagulant. Cost was highlighted as the most significant barrier. Efficacy, dietary freedom and less frequent visits are the major factors affecting the patients' decision.

AB - Warfarin is an anticoagulant medication that is challenging to manage. Dabigatran has been approved by the FDA for stroke and systemic embolism prevention in non-valvular atrial fibrillation as an alternative to warfarin. Dabigatran does not require routine monitoring, has an established dose, and lacks many of the drug, herbal, and food interactions that afflict warfarin. To evaluate patients' satisfaction with their current warfarin treatment and their opinion on switching to a newly marketed medication (dabigatran) through a brief survey. Two separate surveys were administered to (1) evaluate the patients' opinion of their warfarin therapy and (2) evaluate their thoughts on switching to a newer anticoagulant. Responses were recorded on a rating scale of 1-5; 1 being the least and 5 being the highest. Study was conducted at the Georgia Regents Health System (GRHS) pharmacy-based anticoagulation clinic. Two hundred sixty patients on warfarin treatment were enrolled. Patients expressed high satisfaction with warfarin treatment (4.7 ± 0.78). However, a vast majority of the patients were willing to switch to an agent that: requires less frequent follow-up visits (3.9 ± 1.35); lacks interaction with food and/or beverage (4.1 ± 1.25); is as efficacious as warfarin (3.7 ± 1.38). Patients expressed that out-of-pocket cost would be a major barrier to switch to this new medication (1.3 ± 0.58). Patients are satisfied with their warfarin treatment but willing to consider a new anticoagulant. Cost was highlighted as the most significant barrier. Efficacy, dietary freedom and less frequent visits are the major factors affecting the patients' decision.

KW - Atrial fibrillation

KW - Dabigatran

KW - New oral anticoagulants

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84902381185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902381185&partnerID=8YFLogxK

U2 - 10.1007/s11239-013-0976-y

DO - 10.1007/s11239-013-0976-y

M3 - Article

VL - 38

SP - 115

EP - 120

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -